Evolving Industry Partnerships and Investments in Cell and Gene Therapies

Devyn M Smith; Emily J Culme-Seymour; Chris Mason

doi:10.1016/j.stem.2018.03.004

Evolving Industry Partnerships and Investments in Cell and Gene Therapies

Cell Stem Cell. 2018 May 3;22(5):623-626. doi: 10.1016/j.stem.2018.03.004. Epub 2018 Apr 12.

Authors

Devyn M Smith¹, Emily J Culme-Seymour², Chris Mason³

Affiliations

¹ Sigilon Therapeutics, 100 Binney Street, Suite 600, Cambridge, MA 02142, USA. Electronic address: devyn@sigilon.com.
² Gene Therapy, Rare Diseases Unit, R&D, GSK, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK.
³ Advanced Centre for Biochemical Engineering, University College London, Bernard Katz building, London, WC1E 6BT, UK; AVROBIO, One Kendall Square, Bldg 300, #201, Cambridge, MA 02139, USA.

PMID: 29656942
DOI: 10.1016/j.stem.2018.03.004

Abstract

Cell and gene therapies hold the promise of providing significant and durable health gains to patients in many disease states and have recently elicited significant investor and partner interest. We cover the current state of industry partnerships and investments, highlight what makes a partnership advantageous, and discuss implications for stem cell therapies.

Publication types

Review

MeSH terms

Animals
Cell- and Tissue-Based Therapy*
Genetic Therapy*
Humans
Stem Cells / cytology*